ERBB2 and breast carcinoma: Furthermore, microsphere-based QD carriers can be functionalized with targeting ligands such as monoclonal antibodies, aptamers, or peptides, increasing their specificity toward breast cancer biomarkers such as HER2, EGFR, or folate receptors.